Treatment is free for all eligible patients

Study Name : CR 201-MBC

A Multicenter, Double-Blind, Randomized, Parallel- Group, Active-Controlled, Two Part, Phase III, Global Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison with Herceptin®-EU in Patients with HER2-Positive Early Breast Cancer (EBC) and HER2-Positive Metastatic Breast Cancer (MBC).

CTRI/2020/04/024456
read more

Study Name : LAURA

A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA)

CTRI/2018/10/016042
read more

Study Name : KEYNOTE 593

A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)

CTRI/2018/12/016591
read more

Study Name : NILE

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

CTRI/2019/07/020184
read more

Study Name : FLAURA 2

A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)

CTRI/2020/06/025980
read more

Study Name : CALLA

A Phase III Randomized Multi-Center Double-Blind Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)

CTRI/2019/04/018479
read more

Study Name : ADRIATIC

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

CTRI/2019/01/017034
read more

Study Name : AEGEAN

A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and IIINon-small Cell Lung Cancer (AEGEAN)

CTRI/2019/06/019634
read more

Study Name : CAPETILLO 280

A Phase III Double blind Randomised Study Assessing the Efficacy and Safety of Capivasertib plus Paclitaxel Versus Placebo plus Paclitaxel as First line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)

CTRI/2019/08/020833
read more

Study Name : TOPAZ-1

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)

CTRI/2020/08/027208
read more
Book An Appointment